Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. 1989

G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk

UI MeSH Term Description Entries
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077543 Deferiprone A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA. 1,2-Dimethyl-3-hydroxy-4-pyridinone,1,2-Dimethyl-3-hydroxypyrid-4-one,1,2-Dimethyl-3-hydroxypyridin-4-one,3-Hydroxy-1,2-dimethyl-4-pyridinone,DMOHPO,Ferriprox,HDMPP,1,2 Dimethyl 3 hydroxy 4 pyridinone,1,2 Dimethyl 3 hydroxypyrid 4 one,1,2 Dimethyl 3 hydroxypyridin 4 one,3 Hydroxy 1,2 dimethyl 4 pyridinone
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
August 1989, Lancet (London, England),
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
October 1993, British journal of haematology,
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
April 1993, Blood,
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
June 1993, The Journal of the Association of Physicians of India,
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
April 1993, Lancet (London, England),
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
April 1993, Lancet (London, England),
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
November 1990, Lancet (London, England),
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
June 1993, Lancet (London, England),
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
June 1993, Lancet (London, England),
G Vreugdenhil, and A J Swaak, and G J Kontoghiorghes, and H G van Eijk
January 1989, Lancet (London, England),
Copied contents to your clipboard!